Form 4: United Therapeutics Exec Trades Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, executed a series of transactions on April 13, 2026.
• These transactions included the exercise of 9,500 stock options at a price of $146.03 per share, resulting in the acquisition of 9,500 shares of common stock.
• Following the exercise, 35 shares were sold at a weighted average price of $569.7771, and subsequent sales of 925, 945, 1,235, 1,370, 1,850, 1,081, 1,475, 384, and 200 shares occurred at various weighted average prices ranging from $570.83 to $579.526.
• These transactions were conducted under a Rule 10b5-1(c) trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 40,513 shares of common stock directly, with additional holdings through a spouse, and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are routine insider activity conducted under a pre-arranged compliance plan, with no immediate indication of positive or negative company performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures for insider trading.
• The plan allows for continued option exercise and stock sales until December 31, 2026, or until a significant portion of options are exercised, providing flexibility for the reporting person.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market, although conducted under a pre-arranged plan.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of 1,734,410 stock options, creating a timeframe for future transactions.
• Stock options exercised expire on March 17, 2027, indicating a need for future action regarding these options.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until 1,734,410 stock options are exercised, allowing for continued transactions within this period. The stock options themselves expire on March 17, 2027.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a CEO is a common strategy to diversify holdings or manage personal finances while adhering to insider trading regulations, especially in the biotechnology sector where stock price can be volatile.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may lead to short-term market perception shifts, though the plan itself is designed to mitigate insider trading concerns.
• Employees: The transactions do not directly impact employees but reflect executive compensation and financial management strategies.
• Creditors: No direct impact on creditors is indicated by these transactions.

Next Steps

• Continue executing the 10b5-1 trading plan until its termination conditions are met (December 31, 2026, or exercise of 1,734,410 options).
• Manage remaining stock options before their expiration on March 17, 2027.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, United Therapeutics, UTHR, Beneficial Ownership, Common Stock, Executive Transactions